• Contact Us
  • About
  • Advertise
  • Careers
Tuesday, July 1, 2025
Kashmir Dot Com
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us
  • Login
No Result
View All Result
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us
No Result
View All Result
Kashmir Dot Com
No Result
View All Result
Home World

UK approves world’s 1st gene therapy to treat sickle-cell, thalassemia

Kashmir Dot Com by Kashmir Dot Com
November 18, 2023
0
UK approves world’s 1st gene therapy to treat sickle-cell, thalassemia
0
SHARES
2
VIEWS
Share on Facebook

London, Nov 18: The UK has approved the world’s first gene therapy to treat blood disorders sickle-cell disease and thalassemia using the gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020.

So far, a bone marrow transplant — which must come from a closely matched donor and carries a risk of rejection — has been the only permanent treatment option.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorised the new treatment called Casgevy for patients with sickle-cell disease and transfusion-dependent beta-thalassemia aged 12 and over.

Both sickle cell disease and beta-thalassemia are genetic conditions caused by errors in the genes for haemoglobin, which is used by red blood cells to carry oxygen around the body.

Casgevy is designed to work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin.

To do this, stem cells are taken out of bone marrow, edited in a laboratory and then infused back into the patient after which the results have the potential to be life-long.

In people with sickle cell disease, the genetic error can lead to attacks of very severe pain, serious and life-threatening infections, and anaemia (whereby your body has difficulty carrying oxygen). Among beta-thalassaemia patients, it can lead to severe anaemia. Patients often need a blood transfusion every 3 to 5 weeks, and injections and medicines throughout their lives.

“Both sickle cell disease and beta-thalassemia are painful, life-long conditions that in some cases can be fatal,” said Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA, in a statement.

“We have authorised an innovative and first-of-its-kind gene-editing treatment called Casgevy, which in trials has been found to restore healthy haemoglobin production in the majority of participants with sickle-cell disease and transfusion-dependent beta-thalassaemia, relieving the symptoms of disease,” she added.

Casgevy’s approval for sickle-cell disease was based on a clinical trial of 29 patients, of which 28 (97 per cent) were free of severe pain crises for at least 12 months after treatment.

Of the 42 patients in the clinical trial for transfusion-dependent beta-thalassemia, 39 (93 per cent) did not need a red blood cell transfusion for at least 12 months after treatment. The remaining three had more than a 70 per cent reduction in the need for red cell transfusions.

Side effects from treatment were similar to those associated with autologous (from a person’s own cells) stem cell transplants, including (but not limited to) nausea, fatigue, fever and increased risk of infection.

No significant safety concerns were identified during the trials, the MHRA said, adding that the safety of the treatment will be analysed further.

Casgevy is currently being evaluated by the US Food and Drug Administration (FDA) and is expected to receive the agency’s approval next month. IANS

ShareTweetSendSharePinShare
Previous Post

Anxiety mounts for families of workers trapped at Uttarkashi Tunnel collapse site

Next Post

Kulgam encounter: Army commander compliments troops for meticulous planning, execution

Related Posts

President Trump threatens to strip Harvard University of its tax-exempt status

Trump says ‘very big’ trade deal coming up with India

June 27, 2025
‘Hard Slap to America’s Face’: Khamenei Resurfaces, Claims Victory Over Israel

‘Hard Slap to America’s Face’: Khamenei Resurfaces, Claims Victory Over Israel

June 26, 2025

Pakistan Developing Nuclear-Capable ICBM That Can Hit US, Says Intelligence Report

June 25, 2025

Pak PM Expresses Readiness For ‘Meaningful Dialogue’ With India

June 25, 2025

India Breaks Into Top 100 in Global SDG Rankings for First Time

June 24, 2025

Saudi Arabia, Russia offer oil supply continuity for India amid Iran’s Hormuz uncertainty

June 23, 2025
Next Post
Kulgam encounter: Army commander compliments troops for meticulous planning, execution

Kulgam encounter: Army commander compliments troops for meticulous planning, execution

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

ADVERTISEMENT

LATEST NEWS

We Do Not Fear Terrorists: Amarnath Pilgrims Opt For Pahalgam Route Despite Shadow Of April 22 Carnage

Railway Ministry Hikes Fares Of AC Classes By 2 Paise, Non-AC By 1 Paisa Per Km From July 1

ACB arrests Patwari for accepting bribe

LG Sinha visits Baltal, reviews preparedness ahead of Shri Amarnath Ji Yatra

Reshuffle in J&K Anti-Corruption Bureau

6000 students participate in NMMSS examination

Committee on Petitions holds meeting in Srinagar

Srinagar Police Attaches Residential Property Worth Rs 50 Lakh

Markets fall in early trade after 4-day rally dragged by bank stocks

Offline registration for Amarnath Yatra begins today in Jammu

ADVERTISEMENT

About Us

Kashmir Dot Com (KDC) is J&K's premier News Agency having a vast reach of audience.

Kashmir Dot Com is a News Agency based in Srinagar, J&K that offers syndicated multimedia news feed to plethora of news-bureaus in J&K and beyond. We also provide a range of facilities from foreign and domestic channels to package their reports in Jammu and Kashmir. We cover almost all areas of interest in J&K to viewers including news, entertainment, and life styles, bussiness, sports, human-interest features and social and developmental issues.

KDC can well and truly take pride in the legacy of it's work, and in it's contribution towards the building of a free and fair Press in Jammu and Kashmir.

Category

  • Business
  • Entertainment
  • Health
  • JAMMU
  • Kashmir
  • Lead
  • National
  • Opinion
  • Politics
  • Science
  • Sports
  • Tech
  • Uncategorized
  • World

Company Info

  • Contact Us
  • About
  • Advertise
  • Careers
  • Contact Us
  • About
  • Advertise
  • Careers

© 2020 KDC

No Result
View All Result
  • Home
  • Kashmir
  • Jammu
  • World
  • Politics
  • Opinion
  • Business
  • Health
  • Contact Us

© 2020 KDC

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In